Cytomegalovirus retinitis during chemotherapy with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone.
Libby
Edward
E
University of New Mexico, Albuquerque, NM, USA.
Movva
Sujana
S
Quintana
Dulcinea
D
Abdul-Jaleel
Maryam
M
Das
Arup
A
D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects; D017726:Cytomegalovirus Retinitis / Q000150:complications / Q000188:drug therapy / Q000209:etiology*; D003907:Dexamethasone / Q000009:adverse effects; D004317:Doxorubicin / Q000009:adverse effects; D015774:Ganciclovir / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008875:Middle Aged; D009894:Opportunistic Infections / Q000175:diagnosis; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications / Q000188:drug therapy; D000069283:Rituximab; D014750:Vincristine / Q000009:adverse effects
D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab; D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D015774:Ganciclovir